Mark Francois

Raising awareness, delivering more research, including into new treatments, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving cancer survival.

NHS England has implemented non-symptom specific pathways for patients who present with non-specific symptoms, or combinations thereof, that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. Using its national evaluation, NHS England has determined that blood cancers are one of the most common cancer types diagnosed through these pathways.

Professor Lord Darzi is currently undertaking an independent investigation into the state of the National Health Service, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. The Government will set out any further priorities on cancer and health in due course.

The NHS Long-Term Plan, published in January 2019, sets out the NHS’s key ambitions on cancer. The plan sets out the ambition to increase the number of cancers diagnosed at stage one and two to 75% by 2028, and to increase the number of people surviving cancer for five years by 55,000 as a result.

The age-standardised, one-year net survival for adults, those aged 15 to 99 years old, diagnosed with leukaemia between 2016 and 2020 in England was 74.4%, and the five-year survival rate was 55.9%.

NHS England has implemented non symptom specific pathways for patients who present with non-specific symptoms or combinations thereof, that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. The national evaluation showed that blood cancers are one of the most common cancer types diagnosed through these pathways.

Raising awareness, delivering more research, including into new treatments, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving cancer survival.

Cancer patients are being failed, waiting too long for a diagnosis and treatment. We will bring down waits for cancer appointments with the Fit For the Future fund, doubling the number of state-of-the-art magnetic resonance imaging and computed tomography in the National Health Service to ensure early diagnosis and faster treatment.

NHS England has committed to ensuring that all cancer patients have access to a Holistic Needs Assessment, ensuring care is focused on what matters most to each person.

The 2023 England National Cancer Patient Experience Survey indicates the proportion of people with Leukaemia who reported having had a discussion with a member of the team looking after them, before their treatment started, about their needs or concerns was 72.6%. For people with Leukaemia, a further 24.5% said they had the discussion to some extent, and a total of 97.1% reported having had a discussion.

Cancer waiting time data is collected by NHS England according to three performance standards: the Faster Diagnosis Standard (FDS), which aims to ensure patients have cancer diagnosed or ruled out within 28 days of referral from a general practice or screening service; the 31-day wait from a decision to treat to first or subsequent treatment of cancer combined standard; and the 62-day referral to first definitive treatment for cancer combined standard.

Data can then be broken down by cancer type. For the FDS, data regarding leukaemia and its sub-types is collected using the following two categories, suspected acute leukaemia and suspected haematological malignancies, excluding acute leukaemia. The latter category includes non-acute leukaemia when there is a suspicion. These statistics are published monthly and are available at the following link:

https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/